Home > Compound List > Product Information
Latamoxef_Molecular_structure_CAS_64952-97-2)
Click picture or here to close

Latamoxef

Catalog No. DB04570 Name DrugBank
CAS Number 64952-97-2 Website http://www.ualberta.ca/
M. F. C20H20N6O9S Telephone (780) 492-3111
M. W. 520.4726 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 4138

SYNONYMS

IUPAC name
(6R,7R)-7-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
IUPAC Traditional name
latamoxef
Synonyms
moxalactam

DATABASE IDS

PubChem SID 46505546
PubChem CID 47499
CAS Number 64952-97-2

PROPERTIES

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections. [PubChem]
Indication Latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins. It is used to treat bacterial infections. Latamoxef is primarily indicated in conditions like Bone and joint infection, GI infections, Gynecological infections, Meningitis, Respiratory tract infections, Septicaemia, Skin infections, Soft tissue infections, UTI.
Pharmacology Latamoxef works by inhibiting bacterial cell wall biosynthesis.
Toxicity Latamoxef produces potentially life-threatening effects which include Bleeding, Hypothrombinemia, Platelet dysfunctioning. which are responsible for the discontinuation of Latamoxef therapy.
The symptomatic adverse reactions produced by Latamoxef are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Skin rashes, Hematuria, Hyperuricemia, Pyuria, Raised serum creatinine.
Absorption Rapidly absorbed after oral administration.
Half Life 1.6 hours
Protein Binding 40%
Elimination Renal Excretion accounts for 75 %
Distribution 8.51 L
References
Weitekamp MR, Aber RC: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983 Jan 7;249(1):69-71. [Pubmed]
Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M: Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986 Nov;146(11):2159-64. [Pubmed]
External Links
Wikipedia

REFERENCES

  • Weitekamp MR, Aber RC: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983 Jan 7;249(1):69-71. Pubmed
  • Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M: Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986 Nov;146(11):2159-64. Pubmed